MeiraGTx Holdings plc (MGTX) stock
MGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/3065% below fair value
$8.14−0.18 (-2.16%)
Close on Nov 19, 2026Market cap $781.79MP/E 11.5Yield –
MeiraGTx net income
Net income is the profit left for shareholders after every expense, interest and tax.
MeiraGTx's net income for the twelve months ending Jun 30, 2026 was $78.98M. For fiscal 2025 it was -$114.20M. The highest annual figure on record is -$31.04M in fiscal 2017.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$114.20M | – |
| FY2024 | Dec 31, 2024 | -$147.79M | – |
| FY2023 | Dec 31, 2023 | -$84.03M | – |
| FY2022 | Dec 31, 2022 | -$129.62M | – |
| FY2021 | Dec 31, 2021 | -$79.56M | – |
| FY2020 | Dec 31, 2020 | -$57.99M | – |
| FY2019 | Dec 31, 2019 | -$54.75M | – |
| FY2018 | Dec 31, 2018 | -$82.87M | – |
| FY2017 | Dec 31, 2017 | -$31.04M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $160.72M | – |
| Q1 FY2026 | Mar 31, 2026 | -$46.31M | – |
| Q4 FY2025 | Dec 31, 2025 | $15.09M | – |
| Q3 FY2025 | Sep 30, 2025 | -$50.51M | – |
| Q2 FY2025 | Jun 30, 2025 | -$38.80M | – |
| Q1 FY2025 | Mar 31, 2025 | -$39.98M | – |
| Q4 FY2024 | Dec 31, 2024 | -$39.40M | -294.9% |
| Q3 FY2024 | Sep 30, 2024 | -$39.33M | – |
| Q2 FY2024 | Jun 30, 2024 | -$48.62M | – |
| Q1 FY2024 | Mar 31, 2024 | -$20.44M | – |
| Q4 FY2023 | Dec 31, 2023 | $20.22M | – |
| Q3 FY2023 | Sep 30, 2023 | -$44.30M | – |
| Q2 FY2023 | Jun 30, 2023 | -$29.58M | – |
| Q1 FY2023 | Mar 31, 2023 | -$30.36M | – |
| Q4 FY2022 | Dec 31, 2022 | -$27.31M | – |
| Q3 FY2022 | Sep 30, 2022 | -$37.28M | – |
| Q2 FY2022 | Jun 30, 2022 | -$33.97M | – |
| Q1 FY2022 | Mar 31, 2022 | -$31.05M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.91M | – |
| Q3 FY2021 | Sep 30, 2021 | -$25.95M | – |
| Q2 FY2021 | Jun 30, 2021 | -$20.09M | – |
| Q1 FY2021 | Mar 31, 2021 | -$23.62M | – |
| Q4 FY2020 | Dec 31, 2020 | -$10.46M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.43M | – |
| Q2 FY2020 | Jun 30, 2020 | -$25.42M | – |
| Q1 FY2020 | Mar 31, 2020 | -$15.68M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.48M | – |
| Q3 FY2019 | Sep 30, 2019 | -$10.46M | – |
| Q2 FY2019 | Jun 30, 2019 | -$20.82M | – |
| Q1 FY2019 | Mar 31, 2019 | -$17.98M | – |
| Q4 FY2018 | Dec 31, 2018 | -$21.06M | – |
| Q3 FY2018 | Sep 30, 2018 | -$15.42M | – |
| Q2 FY2018 | Jun 30, 2018 | -$29.98M | – |
| Q1 FY2018 | Mar 31, 2018 | -$16.40M | – |
| Q4 FY2017 | Dec 31, 2017 | -$8.60M | – |
| Q3 FY2017 | Sep 30, 2017 | -$8.44M | – |
| Q2 FY2017 | Jun 30, 2017 | -$7.18M | – |
See a number that looks wrong?